US Patent 11,154,516: Scope, Claim-By-Claim Readout, and Competitive Patent Landscape
US Drug Patent 11,154,516 claims a method of treating seizures in patients with treatment-resistant epilepsy specifically Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) using a CBD drug substance with tight impurity/companion-cannabinoid specifications and a defined dose range.
What is claimed in one line?
A seizure-treatment method for LGS/DS that uses a high-purity CBD (≥98% w/w) composition with controlled CBDA, CBDV, Δ9THC, and CBD-C4 impurities and a CBD dose of ~5 to 25 mg/kg/day.
What is the core independent claim scope? (Claim 1)
Claim 1 elements (all required)
-
Indication and patient population
- “A patient in need thereof”
- Seizures associated with treatment-resistant epilepsy
- epilepsy is LGS or DS
-
Treatment modality
- “Administering” a pharmaceutical composition comprising a CBD drug substance
-
CBD drug substance purity and impurity limits
- CBD drug substance comprises:
- at least 98% w/w CBD
- and the remainder comprises:
- (i) not more than 0.15% w/w CBDA
- (ii) not more than 1.0% w/w CBDV
- (iii) not more than 0.15% w/w Δ9THC
- (iv) not more than 0.5% w/w CBD-C4
-
Dose range
- CBD dose: about 5 mg/kg/day to about 25 mg/kg/day
Claim 1 functional scope
- It is a product-defined method claim: the method infringement turns on the composition specs and the administered dose, not on formulation type (oral, liquid, etc.) as long as it is a “pharmaceutical composition” containing the specified “CBD drug substance.”
How do dependent claims tighten coverage? (Claims 2 to 8, 9 to 22, 23 to 30)
A. Composition sub-specifications (Claims 2 to 8)
These claims carve out narrower compositions by specifying which impurity thresholds are met (or additional thresholds are enforced). They do not change the indication, the administration concept, or the dose range unless separately specified later.
| Claims |
Composition requirement (in addition to ≥98% CBD) |
| 2 |
CBDA ≤0.15% w/w |
| 3 |
CBDV ≤1.0% w/w |
| 4 |
Δ9THC ≤0.15% w/w |
| 5 |
CBD-C4 ≤0.5% w/w |
| 6 |
CBDV ≤1.0% w/w and Δ9THC ≤0.15% w/w |
| 7 |
CBDV ≤1.0% w/w, Δ9THC ≤0.15% w/w, CBD-C4 ≤0.5% w/w |
| 8 |
CBDA ≤0.15% w/w, CBDV ≤1.0% w/w, Δ9THC ≤0.15% w/w, CBD-C4 ≤0.5% w/w |
Practical effect: Claims 2-8 give multiple claim paths to infringement even if accused infringers argue about which impurity controls are “material.” Any composition meeting the full set of limits is within Claim 1 and Claim 8; partial compliance still maps to narrower dependent claims if the corresponding impurity condition is satisfied.
B. Efficacy endpoints (Claims 9 to 14)
These claims define treatment benefit in seizure metrics.
| Claims |
Added limitation |
| 9 |
“treats convulsive seizures” |
| 10 |
“reduces seizure frequency” |
| 11 |
reduces “total convulsive seizure frequency” by at least 50% vs baseline |
| 12-14 |
same set as 9-11 but dependent from Claim 8 (composition sub-range alignment) |
Practical effect: Claim 11 is the strongest measurable efficacy limiter in the set: ≥50% reduction in total convulsive seizure frequency vs baseline period. Depending on the claim chart and evidence standards, these claims can function as fallbacks if composition proof is strong but clinical effect proof is disputed, or vice versa.
C. Dose fixed points (Claims 15 to 22)
These lock the dose to specific values while inheriting the method and composition framework of Claim 1.
| Claims |
Dose limitation |
Efficacy add-on |
| 15 |
CBD dose “about 10 mg/kg/day” |
none |
| 16 |
CBD dose “about 20 mg/kg/day” |
none |
| 17 |
(from 15) treats convulsive seizures |
adds “treats convulsive seizures” |
| 18 |
(from 15) reduces seizure frequency |
adds “reduces seizure frequency” |
| 19 |
(from 15) reduces convulsive seizure frequency ≥50% vs baseline |
adds strongest efficacy |
| 20 |
(from 16) treats convulsive seizures |
adds “treats convulsive seizures” |
| 21 |
(from 16) reduces seizure frequency |
adds “reduces seizure frequency” |
| 22 |
(from 16) reduces convulsive seizure frequency ≥50% vs baseline |
adds strongest efficacy |
Practical effect: If a competitor’s regimen uses 10 or 20 mg/kg/day, the patent’s “about” wording can still capture product dosing close to those points, and dependent claims create multiple evidentiary ways to establish infringement.
D. Indication-specific versions with specific dose options (Claims 23 to 30)
These claims tie the syndrome type to the dose and to the ≥50% endpoint.
| Claims |
Syndrome |
Dose limitation |
Efficacy limitation |
| 23 |
LGS |
dose about 10 mg/kg/day or about 20 mg/kg/day |
none (yet) |
| 24 |
(from 23) |
same |
convulsive seizure frequency ≥50% vs baseline |
| 25 |
(from 23) |
about 10 mg/kg/day |
none |
| 26 |
(from 23) |
about 20 mg/kg/day |
none |
| 27 |
DS |
dose about 10 mg/kg/day or about 20 mg/kg/day |
none (yet) |
| 28 |
(from 27) |
same |
convulsive seizure frequency ≥50% vs baseline |
| 29 |
(from 27) |
about 10 mg/kg/day |
none |
| 30 |
(from 27) |
about 20 mg/kg/day |
none |
Practical effect: These are high-value because they cover the two most clinically common “anchor” dosing points and force syndrome-anchored infringement arguments.
What is the effective claim “coverage shape” across composition, dose, and efficacy?
Coverage dimensions
-
Therapeutic area and population
- LGS and DS, seizure control for treatment-resistant epilepsy
-
Molecule definition by specification
- “CBD drug substance” is defined by:
- ≥98% w/w CBD
- plus caps on CBDA, CBDV, Δ9THC, CBD-C4
-
Dose
- broad: ~5 to 25 mg/kg/day
- narrow “anchor” points: ~10 and ~20 mg/kg/day
-
Efficacy endpoint
- broad: seizure reduction and convulsive seizure treatment
- strong measurable: ≥50% reduction vs baseline
Result
- The patent is engineered to be hard to design around because it combines:
- an indication lock (LGS/DS),
- a tight purity/spec definition (multiple companion cannabinoids/THC),
- and dosing anchors that align to common clinical regimens.
Where can competitors design around this claim? (Practical landscape logic)
Because the claim is conjunctive, design-around options are limited to breaking at least one required limitation:
1) Break the CBD spec limits
Any one of the limits may be used as a “tripwire”:
- CBD <98% w/w (fails the “at least 98%” requirement)
- CBDA >0.15% w/w
- CBDV >1.0% w/w
- Δ9THC >0.15% w/w
- CBD-C4 >0.5% w/w
Business implication: Many CBD isolates and even broader “full spectrum” materials will fail at least one spec, but proving compliance is nontrivial because the claim is tied to the “CBD drug substance” composition at dosing.
2) Break the indication scope
Claim 1 requires LGS or DS as the treatment-resistant epilepsy type.
- Treating other epilepsy syndromes is a potential route, but it depends on how product labels and physician practice align.
3) Break the dose range or anchor points
- If the administered CBD dose does not fall in ~5 to 25 mg/kg/day, Claim 1 falls away.
- If the regimen avoids ~10 and ~20 mg/kg/day, the dependent claim stack tied to those points becomes a weaker enforcement basis.
4) Break the efficacy endpoint for evidentiary posture
Even if composition and dosing match, the “≥50% vs baseline” dependent claims (11, 14, 19, 22, 24, 28) depend on measurable endpoints. If evidence is limited or endpoint criteria are not met, narrower dependent claims can be harder to enforce while broader “treats/reduces” claims may still be pursued.
How does this patent fit into the broader US CBD-for-seizures patent landscape?
Landscape pattern
US CBD seizure patents and continuations typically share three recurring claim strategies:
- Syndrome-linked method claims (LGS/DS)
- Product spec-defined claims (CBD purity, THC limits, and impurity profiles)
- Dose range and clinical endpoint dependent claims (including percent seizure reduction)
US 11,154,516 is aligned to that structure, but it is notably specific in enumerating impurity identities and hard caps for:
This combination increases enforcement leverage because it creates multiple independent factual hooks: identity/purity assay data, dosing records, and clinical endpoint evidence.
Competitive implications by strategy
- Generic or “authorized copy” CBD products that are matched to high-purity CBD isolates with tight THC/CBDA controls face higher infringement risk if their clinical use tracks LGS/DS treatment and dose.
- Broad-spectrum or multi-cannabinoid formulations can lower risk on the “≥98% CBD” and impurity cap elements, but may incur risk elsewhere in the landscape if other patents cover their particular cannabinoid ratios or treatment methods.
- Non-CBD anti-seizure drugs avoid this claim entirely by molecule substitution, but may still overlap if other patents cover combination therapy, adjunctive dosing, or seizure-management methods.
Claim chart ready readout for enforcement and FTO
Elements to lock in for infringement analysis
-
Patient condition
- diagnosed with LGS or DS as treatment-resistant epilepsy
-
Administered product
- pharmaceutical composition containing a CBD drug substance meeting:
- ≥98% w/w CBD
- CBDA ≤0.15% w/w
- CBDV ≤1.0% w/w
- Δ9THC ≤0.15% w/w
- CBD-C4 ≤0.5% w/w
-
Dose
- CBD dose in ~5 to 25 mg/kg/day
- or specifically ~10 and/or ~20 mg/kg/day for dependent claim exposure
-
Observed seizure outcome
- convulsive seizures treated/reduced (dependent proof paths)
- and if pursuing strongest dependent claims: ≥50% reduction vs baseline
What does the claims set imply about litigation posture?
-
Multiple fallback routes
- If a defendant contests composition proof, dependent claims still allow alternative evidence pathways on sub-spec compliance.
- If a defendant contests clinical effect, “treats convulsive seizures” and “reduces seizure frequency” still provide lower-threshold hooks than the ≥50% endpoints.
-
High value on dosing documentation
- The “about” dose framing and the fixed anchors (10 and 20 mg/kg/day) are built for medical record-based proof.
-
High evidentiary value on assay results
- Because the CBD drug substance is defined by enumerated impurities, analytical chemistry data becomes central to infringement or invalidity challenges.
Key Takeaways
- Independent Claim 1 requires a LGS or DS treatment-resistant epilepsy seizure method using a ≥98% w/w CBD substance with caps on CBDA, CBDV, Δ9THC, and CBD-C4, at ~5 to 25 mg/kg/day.
- The dependent claims create a stacked enforcement framework across:
- impurity-composition subsets (Claims 2-8),
- seizure outcome categories including ≥50% reduction vs baseline (Claims 11, 14, 19, 22, 24, 28),
- and dosing anchors ~10 and ~20 mg/kg/day (Claims 15-16, 23-30).
- Competitive design-around is principally about breaking at least one conjunctive requirement: CBD purity/impurity caps, indication, or dose range/anchor points.
FAQs
1) What is the single biggest scope driver in US 11,154,516?
The CBD drug substance definition: ≥98% w/w CBD with quantified caps on CBDA, CBDV, Δ9THC, and CBD-C4, combined with LGS/DS and ~5 to 25 mg/kg/day.
2) Does the patent require a specific formulation type (tablet, oil, etc.)?
No such limitation appears in the claim text you provided; it requires a “pharmaceutical composition comprising” the specified CBD drug substance.
3) Which claims include the strongest clinical endpoint?
The claims with “at least 50% compared to baseline” include Claims 11, 14, 19, 22, 24, and 28.
4) Are 10 mg/kg/day and 20 mg/kg/day explicitly covered even though Claim 1 is a range?
Yes. Dependent claims explicitly cover about 10 mg/kg/day (Claims 15-19) and about 20 mg/kg/day (Claims 16, 20-22), and syndrome-specific versions lock these doses to LGS (Claims 23-26) and DS (Claims 27-30).
5) What is the fastest design-around lever in a typical CBD product portfolio?
Matching or exceeding any of the impurity caps is the most straightforward lever on-paper: e.g., failing Δ9THC ≤0.15%, CBDA ≤0.15%, CBDV ≤1.0%, or CBD-C4 ≤0.5% would avoid the claim’s CBD-spec requirements.
References (APA)
[1] US Patent 11,154,516. (n.d.). Method of treating seizures with cannabidiol drug substance for Lennox-Gastaut or Dravet syndrome.
